Salahuddin Anach1, Bulbul Parveen1, Syed Nesar Ahmed1, Md. Khairul Hassan Jessy2, Bashir Ahmed2, Mohammed Shahedur Rahman Khan2

Abstract
Idiopathic pulmonary fibrosis (IPF) is a subtype of diffuse parenchymal lung diseases which is associated
with significant morbidity and mortality. There have been a lot of advancements in the treatment of the
disease in the recent past. Pirfenidone and nintedanib are the most effective treatments currently available
for IPF. The choice between the two drugs should be individualized considering the side effects, comorbidities
and cost.
Keywords: Idiopathic pulmonary fibrosis (IPF), Pirfenidone, Nintedanib

Download PDF